Robotic Versus Conventional Therapy For Post-Stroke Hand Motoric Recovery

November 24, 2023 updated by: Bumi Herman, Hasanuddin University

Comparison Of Robotic And Conventional Mirror Therapy On Hand Motoric Recovery And Functional Outcomes For Rehabilitation Of Post-Stroke Patients

This clinical trial aims to compare the effectiveness of Robotic versus conventional mirror therapy among post-stroke patients. The main questions it aims to answer are:

  • Effectiveness of both interventions in hand motoric recovery across time
  • Effectiveness of both interventions in functional outcomes across time
  • Clinical outcome difference between both interventions Participants will be allocated into either a robotic group as the main intervention or a mirror therapy group as the active comparator. A serial follow-up will be conducted to assess the selected clinical outcome and differences in outcome

Study Overview

Detailed Description

  1. Research design This research is an experimental study with a randomized controlled trial research design.
  2. Study Setting The research will be carried out among post-stroke patients at two teaching hospitals and one physical rehabilitation centre in Makassar
  3. Procedure

    1. Robotic Procedure an exoskeletal robot (Syrebo) will help and stimulate the movement of the paralyzed extremity. One set of training covering Activity Daily Living (ADL) set will be conducted. A mirror will reflect the movement of the healthy extremities
    2. Conventional Method the difference from the robotic procedure was, the movement and stimulation will be provided by the physical therapist.
  4. Time frame the procedure will be conducted in parallel three times per week for a total of six weeks
  5. Outcomes

    1. motoric ability of upper extremity using Fugl-Meyer Assessment for Upper Extremities (FMA-UE)
    2. Dexterity, coordination and response of finger using the Nine Hole Peg Test (NHPT)
  6. Covariates and potential confounders

    1. type of stroke determined by radiology imaging
    2. phase of stroke (acute, sub-acute or chronic)
    3. cognitive ability measured using mini-mental state examination (MMSE)
    4. Spasticity measured by the Modified Ashworth Scale (MAS)
  7. Procedure The data collected is primary data obtained in accordance with the inclusion criteria.

    Samples who are willing to become research subjects will undergo interviews, physical examinations, FMA-UE-Hand Motor Domain and NHPT examinations. The interview questionnaire in this study will contain a list of patient identities including name, age, marital status, address, educational history, employment history, history of stroke, cognitive examination (MMSE), and self-reported visual ability.

    The FMA-UE-Hand Motor Domain scoring system is used to evaluate upper extremity motor function in patients with neurological disorders, such as stroke. The scoring system ranges from 0-14, with higher scores indicating better motor function. The FMA-UE-Hand Motor domain assessment system is broken down into several subscales, namely Mass Flexion and Extension movements, followed by functional movements of grasping (Grasp), including Hook Grasp, Thumb Adduction, Pincer Grasp, Cylinder Grasp, and Spherical Grasp. The assessment will get a score of 0 = None or no movement, 1 = Partial or limited movement, and 2 = Full or perfect movement.

    The NHPT assessment consists of a square board with 9 pegs. At one end of the board, there is a hole for the peg, and at the other end, there is a shallow round plate for holding the peg. NHPT is performed by having the patient take pegs from a container, one at a time, and place them into the holes in a board, as quickly as possible. The patient must then remove the pegs from the holes, one at a time, and reinsert them into the housing. To practice and register initial scores, the test must be started with the unaffected upper limb. The board should be placed in the centre of the patient's body with the housing holding the pegs oriented toward the hand being tested. Only the hand being evaluated should perform the test. The non-evaluated hand is allowed to grip the edge of the board to provide stability. Patients are scored based on the time required to complete the test activity, recorded in seconds. The stopwatch must start from the moment the participant touches the first peg until the last peg touches the container. This assessment requires a board, of wood or plastic, with 9 holes (10 mm diameter, 15 mm depth), spaced 32 mm or 50 mm apart and a stopwatch.

  8. Sample Size Based on previous research, the value of the standard deviation of the selected outcome = 11.5 and the value of x1-x2 = 9.1 (Lin, 2020). The Zα value = 1.96 with a confidence interval of 95% and the Zβ value = 0.84 with a power of 80%, two arms and a dropout rate of 30% at least 40 participants should be recruited. A consecutive sampling will be applied and allocated randomly using the simple randomization technique.
  9. Proposed Statistical Analysis Data on the effect of robotic mirror therapy compared to conventional mirror therapy will be assessed using the independent t-test. Data from the FMA-UE and NHPT assessments before and after the intervention will be analyzed using the paired t-test. Next, the relationship between the FMA-UE and NHPT values will be assessed using the Pearson correlation test (normally distributed data) or the Spearman test (data not normally distributed) to determine how big the correlation is between these variables.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • South Sulawesi
      • Makassar, South Sulawesi, Indonesia, 90245
        • Hasanuddin University, Faculty of Medicine
        • Contact:
        • Principal Investigator:
          • Steven Kurniawan, MD
        • Principal Investigator:
          • Yose Waluyo, MD, PhD
        • Principal Investigator:
          • Husnul Mubarak, MD, PhD
        • Principal Investigator:
          • Nuralam Sam, MD, PhD
      • Makassar, South Sulawesi, Indonesia, 90245
        • Wahidin Sudirohusodo General Hospital
        • Principal Investigator:
          • Steven Kurniawan, MD
        • Principal Investigator:
          • Yose Waluyo, MD, PhD
        • Contact:
        • Principal Investigator:
          • Nuralam Sam, MD. PhD
        • Principal Investigator:
          • Husnul Mubarak, MD
        • Sub-Investigator:
          • Andi A Zainuddin, MD, PhD
        • Sub-Investigator:
          • Andi A Mochtar, Dr, Eng
      • Makassar, South Sulawesi, Indonesia, 90231
        • Cerebellum Clinic
        • Contact:
        • Principal Investigator:
          • Yose Waluyo
        • Principal Investigator:
          • Steven Kurniawan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

  1. Patients aged 20 - 85 years.
  2. Non-haemorrhagic stroke/infarction with onset more than 3 months from the onset of the attack.
  3. Patients with unilateral upper limb hemiparesis.
  4. Modified Ashworth Scale (MAS) on fingers and hands <3
  5. The patient has not undergone mirror therapy treatment before.
  6. Patients who are able to understand informed consent to participate in research.
  7. The patient had a Radiology imaging of the head at the time of stroke onset.

Exclusion criteria:

  1. Patients with severe spasticity or contractures of the upper extremities.
  2. Patients with infarction/bleeding with extensive lesions covering 2 hemispheres.
  3. The patient has severe cognitive impairment that will interfere with the research objectives (MMSE score >24).
  4. Patients post Digital Subtraction Angiography (DSA) procedures in the last 2 months.
  5. Patients with a history of seizures or epilepsy.
  6. Patients with visual field deficits or severe visual impairment.
  7. Patients who are unable to sit upright without assistance.
  8. Other uncontrolled medical conditions (musculoskeletal, neuromuscular, cardiorespiratory) that may interfere with the ability to exercise.

Dropout criteria:

Patients were excluded from the study if:

  1. Participant dies.
  2. Participants take part in the exercise <3 times for 2 consecutive weeks.
  3. The participant refuses to continue the training session.
  4. Participants experience hemodynamic disorders during the training program phase.
  5. Participants experience neurological disorders during the training program phase.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Robotic Mirror Therapy
Serial training with the help of exoskeletal robot therapy
Serial ADL training of upper extremities with robotic aid
Active Comparator: Conventional Mirror Therapy
Serial training with the help of physical therapist
Serial ADL training of upper extremities assisted by physical therapist

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
FMA-UE Score
Time Frame: changes of FMA-UE score from pre-intervention to six weeks after intervention
a motoric assessment with each score range from 0-2 with a total score range from 0-66. Higher score indicates better and free movement
changes of FMA-UE score from pre-intervention to six weeks after intervention
NHPT value
Time Frame: changes of NHPT values from pre-intervention to six weeks after intervention
an assessment for finger dexterity and coordination where the time of the subject to accomplish task will be recorded. Average healthy adult male completed the NHPT in 19.0 seconds (SD 3.2) with the right hand, and in 20.6 seconds (SD 3.9) with the left hand. For healthy adult women, the NHPT was completed in 17.9 seconds (SD 2.8) and 19.6 seconds (SD 3.4) with the right and left hands, respectively.
changes of NHPT values from pre-intervention to six weeks after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Steven Kurniawan, MD, Hasanuddin University
  • Principal Investigator: Nuralam Sam, MD. Ph.D, Hasanuddin University
  • Principal Investigator: Husnul Mubarak, MD, Hasanuddin University
  • Principal Investigator: Yose Waluyo, MD. PhD, Hasanuddin University
  • Principal Investigator: Andi A Zainuddin, MD.Phd, Hasanuddin University
  • Principal Investigator: Andi A Mochtar, Dr. Eng, Hasanuddin University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2023

Primary Completion (Estimated)

February 28, 2024

Study Completion (Estimated)

March 30, 2024

Study Registration Dates

First Submitted

November 24, 2023

First Submitted That Met QC Criteria

November 24, 2023

First Posted (Actual)

December 4, 2023

Study Record Updates

Last Update Posted (Actual)

December 4, 2023

Last Update Submitted That Met QC Criteria

November 24, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

To protect the confidentiality, should the data need to share, any de-identified data will be shared for peer-review

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on SYREBO

Subscribe